Enlivex Therapeutics Management

Management criteria checks 2/4

Enlivex Therapeutics' CEO is Oren Hershkovitz, appointed in Nov 2019, has a tenure of 4.5 years. directly owns 0.1% of the company’s shares, worth €27.94K. The average tenure of the management team and the board of directors is 4.5 years and 6.9 years respectively.

Key information

Oren Hershkovitz

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.5yrs
CEO ownership	0.1%
Management average tenure	4.5yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Oren Hershkovitz's remuneration changed compared to Enlivex Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$29m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	n/a	n/a	-US$31m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$26m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$12m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$296k	US$38k	-US$10m

Compensation vs Market: Insufficient data to establish whether Oren's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Oren's compensation with company performance.

CEO

Oren Hershkovitz (46 yo)

4.5yrs

Tenure

US$295,600

Compensation

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shai Novik	Executive Chairman	10.3yrs	US$536.00k	4.01% $ 1.1m
Oren Hershkovitz	Chief Executive Officer	4.5yrs	US$295.60k	0.10% $ 27.9k
Shachar Shlosberger	Chief Financial Officer	8.3yrs	US$132.00k	0.0050% $ 1.4k
Veronique Amor-Baroukh	Senior Director of Operations	2.3yrs	no data	no data
Sigal Arad	Director of HR	2.3yrs	no data	no data

4.5yrs

Average Tenure

46yo

Average Age

Experienced Management: 1BT's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shai Novik	Executive Chairman	10.3yrs	US$536.00k	4.01% $ 1.1m
Andrew Singer	Independent Director	1.1yrs	no data	no data
Abraham Havron	Independent Director	10.3yrs	no data	0.95% $ 261.8k
Mitchell Levy	Clinical Advisor	no data	no data	no data
Roger Pomerantz	Independent Vice Chairman of the Board	2yrs	no data	no data
Brian Schwartz	Director	3.5yrs	no data	0.0097% $ 2.7k
Clifford Deutschman	Clinical Advisor	no data	no data	no data
James L. Ferrara	Clinical Advisor	no data	no data	no data
Gili Hart	Independent Director	10.3yrs	no data	0.018% $ 4.9k
Mohamad Mohty	Clinical Advisor	no data	no data	no data
Paul Martin	Clinical Advisor	no data	no data	no data

6.9yrs

Average Tenure

59yo

Average Age

Experienced Board: 1BT's board of directors are considered experienced (6.9 years average tenure).

Enlivex Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Recent updates

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

New major risk - Revenue and earnings growth

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

New major risk - Financial position

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Insufficient new directors

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

Enlivex Therapeutics Ltd.: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Enlivex Awards Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Enlivex Therapeutics Ltd Receives Notice of Allowance for Japanese Patent Application

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Announces Issuance of U.S. Patent No. 10,927,343 Covering AllocetraTM, the Immunotherapy Product Candidate

Enlivex Therapeutics Ltd. Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update

New 90-day high: €10.90

Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on Medrxiv

Enlivex Therapeutics Ltd Reports Positive Interim Results of an Investigator-Initiated Phase Ii Clinical Trial Evaluating Allocetratm in Severe and Critical Covid-19 Patients

Enlivex Therapeutics Ltd. Reports Positive Two-Year Clinical Outcome for Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

Enlivex Appoints Dr. Brian Schwartz to the Board of Directors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Reports That the Israeli Ministry of Health Authorized the Initiation of a Proposed Investigator-Initiated Phase II Clinical Trial Evaluating AllocetraTM in Severe and Critical COVID-19 Patients

Enlivex Therapeutics Ltd Reports Positive Top-Line Results of an Investigator-Initiated Clinical Trial of Allocetratm in COVID-19 Patients in Severe/Critical Condition

New 90-day high: €7.40

Enlivex Therapeutics Ltd. Receives New Patent Application Covering ALLOCETRA™

New 90-day low - €3.88

New 90-day low - €4.32

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age